Role of GPR110 on tumorigenesis and metastasis in HER2+breast cancer in the context of anti-HER2 drug resistance

被引：0
|
作者：
Sahay, Debashish
Bhat, Raksha
Rimawi, Motthafar
Osborne, C. Kent
Schiff, Rachel
Trivedi, Meghana V.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
319
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+breast cancer patients with prior anti-HER2 therapy
    Im, S-A
    Bang, Y-J
    Oh, D-Y
    Giaccone, G.
    Bauer, T.
    Nordstrom, J.
    Li, H.
    Moore, P.
    Hong, S.
    Baughman, J.
    Rock, E.
    Burris, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Malwina Stanowicka-Grada
    Elżbieta Senkus
    Current Treatment Options in Oncology, 2023, 24 : 1633 - 1650
  • [43] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [44] The Effect of HER2 Amplification in HER2+Breast Cancer
    Lee, M. K.
    Hurvitz, S. A.
    Tran, B. N.
    Fu, Y.
    Chung, D. U.
    Gornbein, J.
    Apple, S. K.
    Chang, H. R.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S45 - S45
  • [45] GLI2 inhibition suppresses metastasis of HER2+breast cancer
    Gupta, Parul
    Ranjan, Alok
    Fofaria, Neel M.
    Srivastava, Sanjay K.
    CANCER RESEARCH, 2015, 75
  • [46] Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2-positive breast cancer
    Abdulkareem, Noor Mazin
    Bhat, Raksha
    Castillo, Micah
    Jung, Sung Yun
    Vasaikar, Suhas
    Nanda, Sarmistha
    Ruiz, Alexis
    Shea, Martin
    Cao, Wangjia
    Veeraraghavan, Jamunarani
    Kim, Hee-Yong
    Bawa-Khalfe, Tasneem
    Hussain, Tahir
    Liu, Xinli
    Gunaratne, Preethi
    Schiff, Rachel
    Trivedi, Meghana V.
    BRITISH JOURNAL OF PHARMACOLOGY, 2025,
  • [47] Genomic analysis of 733 HER2+breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities
    Ferraro, Emanuela
    Smith, Alison
    Safonov, Anton
    De Lara, Paulino Tallon
    Bernado, Cristina
    Lahuerta, Enrique J. Arenas
    Arribas, Joaquin
    Solit, David
    Reis-Filho, Jorge S.
    Rosen, Neal
    Norton, Larry
    Modi, Shanu
    Robson, Mark E.
    Dang, Chau T.
    Curigliano, Giuseppe
    Chandarlapaty, Sarat
    Razavi, Pedram
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Prospect for anti-HER2 receptor therapy in breast cancer
    Brand, FX
    Ravanel, N
    Gauchez, AS
    Pasquier, D
    Payan, R
    Fagret, D
    Mousseau, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 463 - 470
  • [49] Anti-HER2 therapy for breast cancer in older patients
    Goldner, Marcelle
    Franzoi, Maria A.
    Lago, Lissandra D.
    Ponde, Noam
    FUTURE ONCOLOGY, 2020, 16 (19) : 1393 - 1407
  • [50] Current and future anti-HER2 therapy in breast cancer
    Vrbic, S.
    Pejcic, I.
    Filipovic, S.
    Kocic, B.
    Vrbic, M.
    JOURNAL OF BUON, 2013, 18 (01): : 4 - 16
12345